Medicines and Healthcare products Regulatory Agency

CERTIFICATE NUMBER: UK MIA(IMP) 44168 Insp IMP 44168/21915-0009[I]

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER (1),(2)

Part 1

Issued following an inspection in accordance with:

Part 6 of The Medicines for Human Use (Clinical Trials) Regulations 2004 (SI 2004/1031)

The competent authority of United Kingdom confirms the following:

The Manufacturer: INSTIL BIO (UK) LIMITED

Site address: INSTIL BIO (UK) LIMITED, UNIVERSITY OF MANCHESTER INNOVATION CENTRE, BIOINCUBATOR BUILDING, 48 GRAFTON STREET, MANCHESTER, M13 9XX, UNITED KINGDOM

Has been inspected under the national inspection programme in connection with manufacturing authorisation no. UK MIA(IMP) 44168 in accordance with Part 6 of The Medicines for Human Use (Clinical Trials) Regulations 2004 (SI 2004/1031)

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 15/04/2019, it is considered that it complies with

• The principles and guidelines of Good Manufacturing Practice laid down in Regulation B17 of the Human Medicines Regulations 2012 (as amended)

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in MHRA-GMDP. If it does not appear, please contact the issuing authority.

- (1) Guidance on the interpretation of this template can be found in the Help menu of MHRA-GMDP database.
- (2) These requirements fulfil the GMP recommendations of WHO.

Part 2

Human Investigational Medicinal Products

1. MANUFACTURING OPERATIONS

[1.1] Sterile Investigational Medicinal Products

[1.1.1] Aseptically prepared (processing operations for the following dosage forms)

[1.1.1.4] Small volume liquids

[1.1.1.6] Other aseptically prepared products

Autologus cellular therapies for direct infusion. Allogenic cell therapies

[1.1.3] Batch certification

[1.3] Biological investigational medicinal products

[1.3.1] Biological medicinal products

[1.3.1.3] Cell therapy products

[1.3.1.4] Gene therapy products

[1.3.1.8] Other biological medicinal products

Autologus cellular therapies using cells extracted from human tissue prior to manipulation. The fina

[1.3.2] Batch certification

[1.3.2.3] Cell therapy products

[1.3.2.4] Gene therapy products

[1.3.2.8] Other biological medicinal products

Autologus cellular therapies using cells extracted from human tissue prior to manipulation. The fina

[1.5] Packaging

[1.5.1] Primary packaging

[1.5.1.6] Liquids for internal use

[1.6] Quality control testing

[1.6.1] Microbiological: sterility

[1.6.3] Chemical/Physical

[1.6.4] Biological

2. IMPORTATION OF MEDICINAL PRODUCTS

[2.3] Other Importation Activities

[2.3.2] Importation of Intermediate which undergoes further processing

08/10/2020 Name and signature of the authorised person of the Competent Authority of United Kingdom

Confidential

Medicines and Healthcare products Regulatory Agency

Tel: Confidential

